First Wave BioPharma, Inc.
Simbolis: FWBI
NASDAQ
2.82
USDRinkos kaina šiandien
-0.2784
P/E santykis
0.0000
PEG koeficientas
5.71M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
First Wave BioPharma, Inc. (FWBI) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 10.3 | 3.7 | 1.4 | 8.2 | ||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.net-receivables | 0.02 | 0 | 0.1 | 0 | ||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-current-assets | 4.49 | 1.2 | 2 | 1176268 | ||||||||||
balance-sheet.row.total-current-assets | 14.82 | 5 | 3.4 | 9.4 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 0.98 | 0.2 | 0.3 | 0.4 | ||||||||||
balance-sheet.row.goodwill | 6.74 | 1.7 | 1.7 | 1.9 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 6.74 | 1.7 | 1.7 | 1.9 | ||||||||||
balance-sheet.row.long-term-investments | 0.09 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.tax-assets | -0.06 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-non-current-assets | 0.12 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-non-current-assets | 7.86 | 1.9 | 2 | 2.4 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 22.67 | 6.9 | 5.4 | 11.8 | ||||||||||
balance-sheet.row.account-payables | 3.19 | 0.6 | 0.7 | 2.7 | ||||||||||
balance-sheet.row.short-term-debt | 1.41 | 0.7 | 0.7 | 0.7 | ||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-debt-total | 0.69 | 0.1 | 0.2 | 0.3 | ||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 2.58 | 0.8 | 1.1 | 8 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 0.69 | 0.1 | 0.2 | 7.3 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 0.89 | 0.1 | 0.3 | 0.4 | ||||||||||
balance-sheet.row.total-liab | 12.2 | 3.3 | 2.7 | 19.6 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.retained-earnings | -713.95 | -184.3 | -168.5 | -153.9 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | -1.2 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 724.43 | 187.9 | 171.3 | 147.3 | ||||||||||
balance-sheet.row.total-stockholders-equity | 10.48 | 3.6 | 2.7 | -7.8 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 22.67 | 6.9 | 5.4 | 11.8 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | 10.48 | 3.6 | 2.7 | -7.8 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 22.67 | - | - | - | ||||||||||
Total Investments | 0.09 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-debt | 2.1 | 0.8 | 0.9 | 1 | ||||||||||
balance-sheet.row.net-debt | -8.2 | -2.9 | -0.5 | -7.2 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -15.79 | -15.8 | -14.6 | -58.5 | |||||||||
cash-flows.row.depreciation-and-amortization | 0.03 | 0 | 0 | 0.5 | |||||||||
cash-flows.row.deferred-income-tax | -0.17 | 0.2 | 0 | 3.8 | |||||||||
cash-flows.row.stock-based-compensation | 1.04 | 1 | 0.8 | 1.4 | |||||||||
cash-flows.row.change-in-working-capital | 2.19 | 2.2 | -10.5 | 17.1 | |||||||||
cash-flows.row.account-receivables | 0.09 | 0.1 | -0.1 | 0.6 | |||||||||
cash-flows.row.inventory | 0.75 | 0 | 0.1 | -0.6 | |||||||||
cash-flows.row.account-payables | -0.17 | -0.2 | -2 | 1.4 | |||||||||
cash-flows.row.other-working-capital | 1.51 | 2.3 | -8.5 | 15.7 | |||||||||
cash-flows.row.other-non-cash-items | 0.32 | 0 | 2 | 3.5 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -12.38 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.5 | -0.5 | 0 | -10.3 | |||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.5 | -0.5 | 0 | -10.3 | |||||||||
cash-flows.row.debt-repayment | -0.6 | -0.6 | -0.6 | -507125 | |||||||||
cash-flows.row.common-stock-issued | 9.88 | 15.8 | 23 | 32.7 | |||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 4000000 | |||||||||
cash-flows.row.dividends-paid | 0 | -0.3 | 0 | -4507125 | |||||||||
cash-flows.row.other-financing-activites | 6.04 | 15.4 | -6.6 | 1014262.1 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 15.23 | 15.2 | 15.7 | 44.8 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | -0.3 | 0 | |||||||||
cash-flows.row.net-change-in-cash | 2.35 | 2.3 | -6.9 | 2.2 | |||||||||
cash-flows.row.cash-at-end-of-period | 10.37 | 3.7 | 1.4 | 8.2 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 8.02 | 1.4 | 8.2 | 6.1 | |||||||||
cash-flows.row.operating-cash-flow | -12.38 | -12.4 | -22.3 | -32.3 | |||||||||
cash-flows.row.capital-expenditure | -0.5 | -0.5 | 0 | -10.3 | |||||||||
cash-flows.row.free-cash-flow | -12.88 | -12.9 | -22.3 | -42.6 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.cost-of-revenue | 0.08 | 0 | 0.1 | 0.5 | |||||||||
income-statement-row.row.gross-profit | -0.08 | 0 | -0.1 | -0.5 | |||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.research-development | 5.03 | - | - | - | |||||||||
income-statement-row.row.selling-general-administrative | 10.74 | - | - | - | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.01 | - | - | - | |||||||||
income-statement-row.row.other-expenses | 0 | 0 | -0.2 | 0.5 | |||||||||
income-statement-row.row.operating-expenses | 15.76 | 15.7 | 12.7 | 56.7 | |||||||||
income-statement-row.row.cost-and-expenses | 15.77 | 15.8 | 12.7 | 56.7 | |||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.interest-expense | 0.02 | 0 | 0 | 0 | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.01 | - | - | - | |||||||||
income-statement-row.row.total-other-income-expensenet | -0.02 | 0 | -2 | 0.5 | |||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | -0.2 | 0.5 | |||||||||
income-statement-row.row.total-operating-expenses | -0.02 | 0 | -2 | 0.5 | |||||||||
income-statement-row.row.interest-expense | 0.02 | 0 | 0 | 0 | |||||||||
income-statement-row.row.depreciation-and-amortization | 0.03 | 0 | -0.2 | 3.4 | |||||||||
income-statement-row.row.ebitda-caps | -15.74 | - | - | - | |||||||||
income-statement-row.row.operating-income | -15.77 | -15.8 | -12.7 | -59.1 | |||||||||
income-statement-row.row.income-before-tax | -15.79 | -15.8 | -14.6 | -58.5 | |||||||||
income-statement-row.row.income-tax-expense | 0.02 | 0 | 2 | 0.5 | |||||||||
income-statement-row.row.net-income | -15.81 | -15.8 | -16.6 | -59.1 |
Dažnai užduodami klausimai
Kas yra First Wave BioPharma, Inc. (FWBI) bendras turtas?
First Wave BioPharma, Inc. (FWBI) bendras turtas yra 6883195.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.000.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -8.250.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.000.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.000.
Kas yra First Wave BioPharma, Inc. (FWBI) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -15794983.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 826844.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 15741553.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 3711770.000.